The House of Commons and Glaxo

The Glaxo furore moves into the House of Commons today, as Paul Flynn MP lays down four (yes four) very strongly worded early day motions – will your MP sign?

Your MPs represent you – if you want them to sign make sure they know your feelings…

EDM 769
GLAXOSMITHKLINE 30.01.2007

Flynn, Paul That this House congratulates the previous New York Attorney General, Eliot Spitzer, on his successful law suit which claimed that GlaxoSmithKline (GSK) suppressed four studies that failed to demonstrate that the drug Seroxat was effective in treating children and adolescents and indicated an increase of suicidal thinking and acts; is alarmed by the publication of a leaked GSK document proving they intended to manage the dissemination of data in order to minimise any potential negative commercial impact; and urges GSK to show remorse and to resolve in future to put their customers’ health before GSK profits.

EDM 768
GLAXOSMITHKLINE AND SEROXAT 30.01.2007

Flynn, Paul That this House challenges GlaxoSmithKline (GSK) to act on its vacuous threat to sue the BBC on its evidence that GSK had deliberately suppressed and distorted trial results of the anti-depressant Seroxat to conceal its direct links to suicide in teenagers; notes that GSK’s own unpublished studies showed the drug actually trebles the risk of suicidal thoughts and behaviour in depressed children without any proven benefit over placebos; urges the Medicine and Healthcare Products Regulatory Agency to accelerate its criminal investigation into GSK begun three years ago; and looks forward to an early prosecution of a company that no longer deserves public trust.

EDM 767
CONDUCT OF GLAXOSMITHKLINE 30.01.2007

Flynn, Paul That this House questions the propriety and courtesy of the action of GlaxoSmithKline (GSK) in writing to hon. Members with constituency interests in GSK urging them to oppose Motions for Early Day (EDMs) critical of their conduct, then denying originators of the EDMs details of the content of their messages when requested.

EDM 766
MEDICINAL DRUG TRIALS 30.01.2007

Flynn, Paul That this House notes the collapsing confidence in trials of medicinal drugs by pharmaceutical companies; is alarmed at the mounting evidence that such companies’ trials are overwhelmingly biased in their conclusions compared with independent trials concealing adverse effects that have killed tens of thousands of patients; recalls that Sir Iain Chalmers’ evidence to the Health Select Committee that one anti-arrhythmic drug in the 1980s killed more people than all the Americans killed in the Vietnam war in spite of evidence of its fatal consequences that was suppressed for 13 years; recalls that the Safety Director of the US Food and Drug Administration said that the painkiller Vioxx caused up to 140,000 strokes and heart attacks in the USA alone; notes claims that Merck suppressed information on Vioxx’s dangers in the same way that GlaxoSmithKline denied access to evidence of adverse reactions to Seroxat; and calls for the establishment of an independent drugs testing agency funded by a levy on pharmaceutical companies modelled on the Italian Agenzia Italiana del Farmaco.

You can find a link to Paul Flynn’s website just to the right, in my Blogroll.

3 Responses to “The House of Commons and Glaxo”

  1. ROBERT FIDDAMAN Says:

    EDM 767
    GSK wrote to MP’s asking them to oppose any EDM’s concerning GSK?

    Tell me more

    Bob

  2. admin Says:

    That’s all I know at the moment.

    I guess we should be shocked, but it is Glaxo that we’re talking about – they seem like a desperate bunch to me.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: